Bill
S 6168
Requires insurers to cover single-source drugs (no generics), boosting patient access and reducing out-of-pocket costs.
The bill’s title indicates it would address coverage requirements for single source drugs, i.e., medications that currently have no generic alternatives and are produced by a single manufacturer. While the text of S 6168 is not provided in the materials, the bill’s objective is typically to ensure insurance coverage for such drugs under various health plans, potentially to improve patient access and mitigate affordability or access barriers associated with single-source therapies.
The exact provisions of S 6168 are not provided in the current materials. Based on the title and common policy approaches to single source drugs, possible areas the bill could address (if included) include:
- Requirements for insurer coverage of single-source drugs in preferred formulary placement.
- Limitations or guidelines on step therapy or prior authorization for single-source drugs.
- Protections to prevent discrimination in coverage between single-source drugs and other therapeutics.
- Requirements related to co-pays, cost-sharing, or patient access programs for single-source therapies.
- Procedures for exceptions, appeals, and timely access to medications.
- Reporting or transparency obligations for insurers regarding coverage decisions for single-source drugs.
Note: These items are speculative in the absence of the bill text; the actual provisions may differ.
If you’d like, I can update this summary as soon as the bill text or committee memo becomes available.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
